Moleculin Biotech Analyst Price Targets

Wall Street analyst price targets and consensus rating for Moleculin Biotech (MBRX).

Price Target Range — 10 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$2015Upside to Avg. PT+33397.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 28, 2026	HC Wainwright & Co.	Sara Nik	PT Cut	Buy	$440→$60
Mar 24, 2026	HC Wainwright & Co.	Sara Nik	Maintained	Buy	$440
Dec 11, 2025	HC Wainwright & Co.	Sara Nik	PT Raise	Buy	$80→$440
Sep 10, 2025	HC Wainwright & Co.	Sara Nik	Maintained	Buy	$2000
Aug 27, 2025	HC Wainwright & Co.	Sara Nik	Maintained	Buy	$2000
Jun 18, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$2000
Jun 9, 2025	HC Wainwright & Co.	Joseph Pantginis	Assumes	Buy	$2000
Mar 25, 2025	Maxim Group	Jason McCarthy	Upgrade	Hold→Buy	$2000
Mar 25, 2025	HC Wainwright & Co.	Vernon Bernardino	Maintained	Buy	$4000
Mar 24, 2025	HC Wainwright & Co.	Vernon Bernardino	Maintained	Buy	$4000
Mar 3, 2025	HC Wainwright & Co.	Vernon Bernardino	Maintained	Buy	$4000
Nov 12, 2024	Maxim Group	Jason McCarthy	PT Cut	Buy	$10000→$4000
Apr 12, 2024	Roth MKM	Jonathan Aschoff	Maintained	Buy	$20000
Mar 26, 2024	Maxim Group	Jason McCarthy	PT Cut	Buy	$22500→$10000
Dec 14, 2023	HC Wainwright & Co.	Vernon Bernardino	Initiate	Buy	$22500

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Lowers Price Target to $3

HC Wainwright & Co. analyst Sara Nik maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and lowers the price target from $22 to $3.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $22 Price Target

HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $22 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Raises Price Target to $22

HC Wainwright & Co. analyst Sara Nik maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and raises the price target from $4 to $22.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $4 Price Target

HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $4 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $4 Price Target

HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $4 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $4 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $4 price target.

Benzinga Newsdesk

Moleculin Biotech Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Moleculin Biotech Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Lowers Price Target to $3

PRO
HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $22 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Raises Price Target to $22

PRO
HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $4 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $4 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $4 Price Target

People Also Watch

People Also Watch

Moleculin Biotech Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Moleculin Biotech Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on Moleculin Biotech, Lowers Price Target to $3

PROHC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $22 Price Target

PROHC Wainwright & Co. Maintains Buy on Moleculin Biotech, Raises Price Target to $22

PROHC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $4 Price Target

PROHC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $4 Price Target

PROHC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $4 Price Target

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Lowers Price Target to $3

PRO
HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $22 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Raises Price Target to $22

PRO
HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $4 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $4 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $4 Price Target